Durvalumab

• Target :

  PD-1/PD-L1

• Related Pathways :

  Apoptosis|||Immunology/Inflammation|||Cell Cycle/Checkpoint

• Purity :

  0.972

• Bioactivity :

  Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  1428935-60-7